Nimbus Therapeutics tests a dual inflammation and repair thesis with SIK2 inhibitors
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.
Can Amneal’s Parkinson’s strategy evolve beyond symptoms? KeifeRx tie-up may signal shift
KeifeRx and Amneal join forces on KFRX06, a brain-penetrant LRRK2 inhibitor for Parkinson’s. Find out what this could mean for CNS innovation.
Is Avenzo’s AVZO-021 the next big player in HR+/HER2- metastatic breast cancer?
Avenzo shares Phase 1 data on CDK2 inhibitor AVZO-021 in HR+/HER2- breast cancer. Find out what it means for post-CDK4/6 resistance strategies in 2025.